Tolerability, safety, pharmacokinetics and pharmacodynamics of SHR0534, a potent G protein-coupled receptor 40 (GPR40) agonist, at single- and multiple-ascending oral doses in healthy Chinese subjects
Authors:
- 28 December 2020
- journal article
- research article
- Published by Taylor & Francis in Xenobiotica
- Vol. 51 (3) , 297-306
Abstract
SHR0534 is being developed for type-2 diabetes mellitus. Herein the tolerability, safety, pharmacokinetics and pharmacodynamics of SHR0534 in healthy Chinese subjects were assessed in a phase-I, ra...Keywords
This publication has 48 references indexed in Scilit:
- A Novel Antidiabetic Drug, Fasiglifam/TAK-875, Acts as an Ago-Allosteric Modulator of FFAR1PLOS ONE, 2013
- Risk of Stroke with Thiazolidinediones: A Ten-Year Nationwide Population-Based Cohort StudyCerebrovascular Diseases, 2013
- Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugsDiabetologia, 2012
- Overexpression of GPR40 in Pancreatic β-Cells Augments Glucose-Stimulated Insulin Secretion and Improves Glucose Tolerance in Normal and Diabetic MiceDiabetes, 2009
- Gpr40 Is Expressed in Enteroendocrine Cells and Mediates Free Fatty Acid Stimulation of Incretin SecretionDiabetes, 2008
- Free fatty acids increase cytosolic free calcium and stimulate insulin secretion from β-cells through activation of GPR40Molecular and Cellular Endocrinology, 2007
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialThe Lancet, 2005
- The Orphan G Protein-coupled Receptor GPR40 Is Activated by Medium and Long Chain Fatty AcidsJournal of Biological Chemistry, 2003
- Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40Nature, 2003
- DEVELOPMENT OF RETINOPATHY AND PROTEINURIA IN RELATION TO PLASMA-GLUCOSE CONCENTRATIONS IN PIMA INDIANSThe Lancet, 1980